

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P33108	SERIAL NO. 10/527,866
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Allen et al.	
		FILING DATE 12 Sep 2003	GROUP

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US-10/540371	12 -19 -2003	Allen, et al			
	US-10/596561	12 -17 -2004	Allen, et al			
	US-3,755,340	08 -28 -1973	Hoehn et al.			
	US-3,833,594	09 -03 -1974	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-3,840,546	10 -08 -1974	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-3,856,799	12 -24 -1974	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-3,925,388	12 -09 -1975	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-3,966,746	06 -29 -1976	Hoehn et al. / E.R. Squibb & Sons, Inc.			

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No
CA-1003419	01 -11 -1977	CA			
CH-553 799	09 -13 -1974	CH			X
EP-0 076 035-A1	04 -06 -1983	EP			
JP-2002-20386-A	01 -23 -2002	JP			X
WO-00/15222-A	03 -23 -2000	WO			
WO-02/060900-A	08 -08 -2002	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

	BARE T.M. ET AL.; Synthesis and structure-activity relationships of a series of anxiolytic pyrazolopyridine ester and amide anxiolytic agents; Journal of Medicinal Chemistry; 1989; 32; pages 2561-2573;
	HOEHN H. ET AL.; 1H-pyrazolo[3,4-b]pyridines; Journal of Heterocyclic Chemistry; 1972; 9(2); pages 235-253;
	HOEHN H. ET AL.; Potential antidiabetic agents. Pyrazolo[3,4-b]pyridines.; Journal of Medicinal Chemistry; 1973; 16(12); pages 1340-1346;
	SCHENONE S. ET AL.; Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands; Bioorg. Med. Chem. Lett.; 2001; 11; pages 2529-2531;
	YU G., MASON H.J., ET. AL.; Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction; Journal of Medicinal Chemistry; 2001; 44; pages 1025-1027;

Examiner Signature	Date Considered
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>	<b>ATTY DOCKET NO.</b> P33108	<b>SERIAL NO.</b> 10/527,866
	<b>APPLICANT</b> Allen et al.	
	<b>FILING DATE</b> 12 Sep 2003	<b>GROUP</b>

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US-3,979,399	09 -07 -1976	Hoehn et al. / E.R. Squibb & Sons, Inc.			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation Yes No	
	WO-02/081463-A1	10 -17 -2002	WO				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc)


<b>Examiner Signature</b>	<b>Date Considered</b>
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	